Hyaluronidase 1,500unit powder for solution for injection ampoules
Requires a prescription from a doctor or prescriber
Highly purified sheep hyaluronidase for administration by injection into the vitreous of the eye.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Hyaluronidase
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Hyaluronidase
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
3 branded products available
MHRA licensed products
View all licensed products for Hyaluronidase on the MHRA register
Hyaluronidase 1,500unit powder for solution for injection ampoules
Hyaluronidase 1,500unit powder for solution for injection ampoules
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(3)
Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumab (ESNM13)
Cataracts in adults: management (NG77)
Inducing labour (NG207)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 14 · Randomised trials: 1 · 1947–2026
Showing the 50 most relevant studies, sorted by most relevant.
Bettina Alexandra Buhren, Holger Schrumpf, Norman‐Philipp Hoff, et al.
European journal of medical research, 2016
- Anesthetics, Local
- Biological Availability
- Diffusion
Alhusain AM, Alsaif M, Alkhathami AM, et al.
2026
- Hyaluronoglucosaminidase
- Hyaluronic Acid
- Cosmetic Techniques
Catherine Zhu, MD, Ghassan Barnawi, MD, Elen Grigorchuk, et al.
JAAD International, 2026
Solange Elkallassi
2023
Azizi N, Tootoonchi N, Khorasanizadeh F, et al.
2025
Elman, Scott, Lin, Rachel, Rachel Lin, et al.
2024
Michael K. Paap, T. Milman, Shoaib Ugradar, et al.
Ophthalmic Plastic and Reconstructive Surgery, 2019
K. Girish, K. Kemparaju
Life sciences, 2007
- Extracellular Matrix
- Hyaluronic Acid
- Hyaluronoglucosaminidase
A. Csoka, G. Frost, R. Stern
Matrix biology : journal of the International Society for Matrix Biology, 2001
- Amino Acid Sequence
- Chromosomes, Human, Pair 3
- Chromosomes, Human, Pair 7
E. Menzel, C. Farr
Cancer letters, 1998
- Cell Adhesion
- Hyaluronic Acid
- Hyaluronoglucosaminidase
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
24-48 hours
Mechanism
Hyaluronidase cleaves hyaluronic acid at the glucosaminidic bond between C1 of glucosamine and C4 of glucuronic acid.
Food interactions
None known
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
[L13338]
Half-life
24-48 hours
[A199053][A199065]
Protein binding
[L13338]
Volume of distribution
[L13338]
Metabolism
[L13338]…
Elimination
[A182009][A199065]…
Clearance
[L13338]
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Hyaluronidase was first used in prescription products in the United States on 5 May 2004.[L13338]
[L13338]
Hyaluronidase is also indicated by multiple routes to increase the dispersion of other injectable drugs.
[L13338]
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 196 interactions
[L13338]
In the even of an overdose, treat patients with symptomatic and supportive measures.
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L13338]
[A199053][A199065]
[L13338]
[L13338]
[L13338]
However, protein drugs are expected to be degraded by proteases and other catalytic enzymes to smaller peptides and amino acids.
[A182009]
[A182009][A199065]
[L13338]
Proteins and enzymes this drug interacts with in the body
ATC B06AA03
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Hyaluronidase
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q105488220), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication.